Introduction：Basic information about Muromonab-CD3 CAS 140608-64-6, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Muromonab-CD3 Basic information
| Product Name: | Muromonab-CD3 |
| Synonyms: | Muromonab-CD3;Muromonab-CD3 USP/EP/BP;Research Grade Muromonab(DHC27701);Research Grade Muromonab-Cd3;Research Grade Muromonab;Muromonab (anti-CD3);Muromonab |
| CAS: | 140608-64-6 |
| MF: | |
| MW: | 0 |
| EINECS: | |
| Product Categories: | |
| Mol File: | Mol File |
|
Muromonab-CD3 Chemical Properties
| form | Liquid |
| color | Colorless to light yellow |
Safety Information
Muromonab-CD3 Usage And Synthesis
| Description | Muromonab-CD3 is a murine monoclonal antibody to the T3 antigen of humanT-cells, which blocks their killing ability. It is useful in the treatment of acute allograft rejection in renal transplant patients. |
| Originator | Ortho (USA) |
| Uses | Monoclonal antibody (immunosuppressant). |
| Brand name | OrthocloneOKT3 (Ortho Pharmaceutical);ORTHOCLONE OKT3. |
| General Description | Muromonab-CD3 (murine, Orthoclone-OKT3) is an unmodified mouse immunoglobulin, an IgG2a, monoclonal. It binds a glycoprotein on the surface of mature T lymphocytes. Mature T cells have, as part of the signal transduction machinery of the T-cell receptor complex, a set of three glycoproteins that are collectively called CD3. Together with the protein zeta, the CD3 molecules become phosphorylated when the T-cell receptor is bound to a peptide fragment and the major histocompatibility complex. The phosphorylated CD3 and zeta molecules transmit information into the cell, ultimately producing transcription factors that enter the nucleus and direct the T-cell activity. By binding to CD3, muromonab-CD3 prevents signal transduction into T cells.
Muromonab-CD3 blocks the function of T cells thatare involved in acute renal rejection. Hence, it is indicatedfor the treatment of acute allograft rejection in heart andliver transplant recipients resistant to standard steroidtherapies. |
| Mechanism of action | Muromonab-(CD3) alters the cell-mediated immuneresponse by binding to the CD3 (cluster of differentiationantigen, T3) glycoprotein on T lymphocytes.This binding inhibits lymphocyte activation so that affectedT cells cannot recognize foreign antigen and cannotparticipate in rejecting an organ graft.Within minutesof the first muromonab-(CD3) injection, totalcirculating T cells are rapidly depleted from the blood.They later reappear devoid of CD3 and antigen recognitioncomplexes. |
| Clinical Use | Muromonab-(CD3) (Orthoclone OKT3) is a mousemonoclonal antibody that is a purified IgG. It is usedfor the prevention of acute allograft rejection in kidneyand hepatic transplants and as prophylaxis in cardiactransplantation. It is also used to deplete T cells inmarrow from donors before bone marrow transplantation. |
| Side effects | Adverse side effects include fever, pulmonaryedema, vomiting, headache, and anaphylaxis. Neutralizingantibodies may develop over time and necessitateadjusting the dosage upward to compensate for the lossof therapeutic activity. |
Muromonab-CD3 Preparation Products And Raw materials
